Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863908 | 0.90 | ESR1 (0.48) | ESR1ESR2ABCC1LTA4HHRH3 | |
| SCHEMBL5863643 | 0.89 | ESR1 (0.49) | ESR1ESR2LTA4H | |
| SCHEMBL5863596 | 0.89 | ESR1 (0.46) | ESR1ESR2ABCC1KDM4EPOLB | |
| SCHEMBL5864271 | 0.86 | ESR1 (0.44) | ESR1ESR2LTA4HHRH3 | |
| SCHEMBL5864087 | 0.85 | ESR1 (0.45) | ESR1ESR2ABCC1KDM4ELTA4H | |
| SCHEMBL5863786 | 0.85 | HTT (0.42) | ESR1ESR2KDM4ELTA4H | |
| SCHEMBL5864192 | 0.84 | ESR1 (0.42) | ESR1ESR2ABCC1LTA4HPTGS2 | |
| SCHEMBL5863997 | 0.84 | MMP1 (0.44) | ESR1ESR2ABCC1LTA4HPTGS2 | |
| SCHEMBL5863730 | 0.84 | ESR1 (0.50) | ESR1ESR2KDM4EPOLBLTA4H | |
| SCHEMBL5864170 | 0.82 | MMP1 (0.50) | ESR1ESR2LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | ESR1 4/4885ESR2 12/4885ABCC1 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.